The dementia drug rivastigmine may reduce the risk of falls in patients with Parkinson’s disease by improving gait stability, findings from the phase II ReSponD trial show.
Once-daily opicapone is effective for the treatment of end-of-dose motor fluctuations in patients receiving levodopa for Parkinson’s disease, phase III study findings show.
An analysis of the gait of top Russian officials has led researchers to warn neurologists against interpreting a probable behavioural adaptation as a pathological gait pattern.
Researchers have found positive immunostaining of α-synuclein in the enteric nervous system of patients with idiopathic rapid eye movement sleep behaviour disorder, suggesting it may have a possible role as a biomarker for prodromal Parkinson’s disease.
Researchers report that nearly half of patients with Parkinson’s disease develop cognitive impairment within about a decade, and progress rapidly to dementia.
Research shows that people with a theoretical high risk of developing Parkinson’s disease have significant cognitive deficits, particularly affecting executive function.
Early analysis of cerebrospinal fluid could help diagnose parkinsonian disorders and enhance the prediction of dementia in Parkinson’s disease patients, study results indicate.
Increased serotonergic fibre innervation relative to dopaminergic fibre availability may be a potential marker of disease progression in Parkinson’s disease patients and a possible warning of levodopa-induced dyskinesia, indicates an in vivo imaging study.
Researchers have devised a model that distinguishes patients with Parkinson’s disease from those without the condition without relying on motor features.
Subtle changes in white matter integrity are detectable in patients with Parkinson’s disease and are associated with early impairments in cognition, say researchers.
Around a quarter of patients with Parkinson’s disease end up in a long-term care facility or nursing home, say researchers who highlight the role of neurologists in improving these patients’ care.
Deep-brain stimulation of the subthalamic nucleus may help to restore long-term potentiation-like plasticity in the motor cortex of patients with Parkinson’s disease, a study shows.
Motor fluctuations and dyskinesias affect about a third of community-based patients with Parkinson’s disease, but dyskinesias are rarely severe enough to warrant a change of treatment, report researchers.
Prolonged-release combined oxycodone/naloxone may provide relief for patients with severe pain related to Parkinson’s disease, a double-blind randomised trial shows.
A Taiwanese population-based cohort study reports an increased risk of most cancers in patients with Parkinson’s disease, contrasting with findings in Western populations.